Pyxis Oncology Q2 FY26 net loss widens to $25.3 million
Reuters2026/08/13 11:02- Pyxis Oncology posted a GAAP net loss of USD 25.3 million, or USD 0.40 a share, for Q2 2026.
- R&D expense edged down to USD 16.1 million; manufacturing costs fell, partly offset by higher MICVO trial and preclinical spending.
- G&A expense climbed to USD 9.9 million on higher severance costs and stock-based compensation.
- Cash, restricted cash, and short-term investments totaled USD 34.5 million at June 30; upfront private placement proceeds extended runway into Q2 2027.
- MICVO monotherapy update in 2L+ R/M HNSCC due in Fall 2026; MICVO-Keytruda combination update targeted for Q4 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
OPEC+ agrees to keep oil output policy unchanged for October
US military strikes Iranian oil tanker, triggering geopolitical risks as Brent crude nears $97 mark
Following the US military's attack on Iranian oil tankers and Iran's announcement of new restricted navigation zones outside the Strait of Hormuz, market concerns over prolonged disruptions in key energy transport routes have intensified, leading to a sharp rise in international oil prices.
Geopolitical tensions overshadowing production cuts: OPEC+ maintains quotas unchanged, paper adjustments fail to resolve physical supply dilemmas
OPEC+ major oil producers, led by Saudi Arabia and Russia, held a monthly video conference last Sunday and decided to keep the crude oil production quota for October unchanged, continuing the previous tone of stable production following a series of symbolic production increases.
IX Biopharma seeks SGX-ST trading halt lift for shares in Singapore
Crypto prices
More
